Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TVGN
TVGN logo

TVGN Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
4.540
Open
4.360
VWAP
4.32
Vol
18.05K
Mkt Cap
17.29M
Low
4.135
Amount
78.00K
EV/EBITDA(TTM)
--
Total Shares
4.03M
EV
31.18M
EV/OCF(TTM)
--
P/S(TTM)
--
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
Show More

Events Timeline

(ET)
2026-03-25
14:30:00
Tevogen Regains Nasdaq Compliance
select
2026-03-13 (ET)
2026-03-13
12:40:00
Tevogen.AI Reports Performance Advancements for AI Platform
select
2026-03-09 (ET)
2026-03-09
07:50:00
Tevogen Appoints Interim Leaders to Drive Growth Strategy
select
2026-03-06 (ET)
2026-03-06
15:50:00
Tevogen CEO Updates Strategic Acquisition Plans, Annual Revenue Over $50 Million
select
2026-03-06
10:20:00
Tevogen Bio Holdings Inc Trading Halted Due to Volatility
select
2026-03-05 (ET)
2026-03-05
19:50:00
Tevogen Bio Holdings Inc Trading Halted, News Pending
select
2026-03-05
15:00:00
Tevogen Signs Letter of Intent with Apozeal for Strategic Transaction
select
2026-03-04 (ET)
2026-03-04
08:10:00
Tevogen Approves 1-for-50 Reverse Stock Split
select

News

Newsfilter
8.5
03-26Newsfilter
Tevogen Plans CRO Acquisition to Enhance Growth Potential
  • Potential Revenue Impact: Tevogen is evaluating a CRO acquisition that is expected to generate over $20 million in annual revenue and support double-digit growth, thereby further solidifying its position in oncology and rare diseases.
  • Global Operational Capabilities: The target CRO operates in over 20 countries and possesses extensive global clinical development capabilities, which will enable Tevogen to better meet the needs of clients in complex therapeutic areas, enhancing service quality and market competitiveness.
  • Strategic Development Direction: This acquisition will facilitate Tevogen's transformation into a diversified, cash-flow-oriented healthcare enterprise, with the CEO indicating potential for nearly $100 million in annual revenue, reflecting the company's ambition in medical innovation.
  • Integration of Technology and Innovation: Tevogen leverages artificial intelligence and precision T cell therapy platforms to develop advanced life-saving therapies, with future strategic initiatives potentially including domestic generics and biosimilars to drive sustainable innovation and patient access.
moomoo
7.0
03-25moomoo
TEVOGEN MEETS NASDAQ'S MINIMUM BID PRICE CRITERIA AGAIN
  • Compliance Achievement: Tevogen has regained compliance with NASDAQ's minimum bid price requirement.
  • Regulatory Standards: The company met the necessary standards to avoid delisting from the stock exchange.
moomoo
8.0
03-13moomoo
TEVOGEN BIO HOLDINGS INC - BOARD IS STILL ASSESSING POSSIBLE ONE-TIME SPECIAL CASH DIVIDEND
  • Company Overview: Tevogen Biologics is a biotechnology company focused on developing innovative therapies and treatments.

  • Current Evaluation: The company's board is actively evaluating the potential for a one-time special cash dividend for its shareholders.

moomoo
5.0
03-13moomoo
TEVOGEN BIO HOLDINGS - PRIMARY INVESTOR AFFIRMS PLAN TO KEEP EXISTING SHAREHOLDINGS
  • Company Announcement: Tevogen Biologics has confirmed its intention to maintain its current shareholdings.
  • Investor Communication: The announcement is aimed at reassuring investors about the company's commitment to its existing equity structure.
moomoo
3.5
03-13moomoo
TEVOGEN.AI ANNOUNCES PROGRESS IN PREDICTCELL™ BETA, SHOWCASING ENHANCED ACCURACY METRICS AND GROWING ITS PROPRIETARY AI FRAMEWORK
  • Advancements in Predictive Cell Technology: Tevogen AI reports significant improvements in their Predict Cell™ Beta, showcasing enhanced precision metrics.

  • Expansion of Proprietary AI Infrastructure: The company is also expanding its proprietary AI infrastructure to support these advancements in predictive technology.

Benzinga
9.5
03-09Benzinga
BETA Technologies Reports Disappointing Q4 Results
  • Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
  • Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
  • Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
  • Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.

Valuation Metrics

The current forward P/E ratio for Tevogen Bio Holdings Inc (TVGN.O) is -1.80, compared to its 5-year average forward P/E of -0.93. For a more detailed relative valuation and DCF analysis to assess Tevogen Bio Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.93
Current PE
-1.80
Overvalued PE
0.81
Undervalued PE
-2.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

biotech industry stock under 5 dollars
Intellectia · 282 candidates
Industry: Biotechnology & Medical ResearchPrice: <= $5.00
Ticker
Name
Market Cap$
top bottom
APLT logo
APLT
Applied Therapeutics Inc
14.63M
TOVX logo
TOVX
Theriva Biologics Inc
6.85M
IOBT logo
IOBT
IO Biotech Inc
14.94M
ADIL logo
ADIL
Adial Pharmaceuticals Inc
6.04M
GRI logo
GRI
GRI Bio Inc
2.26M
PPCB logo
PPCB
Propanc Biopharma Inc
3.62M
stovks to buy on wed from 20 to 40 cents
Intellectia · 81 candidates
Price: $0.20 - $0.40
Ticker
Name
Market Cap$
top bottom
SGMO logo
SGMO
Sangamo Therapeutics Inc
127.97M
IXHL logo
IXHL
Incannex Healthcare Inc
123.43M
GPUS logo
GPUS
Hyperscale Data Inc
96.48M
AURE logo
AURE
Aurelion Inc
95.26M
AIIO logo
AIIO
Robo.ai Inc
89.22M
ZONE logo
ZONE
CleanCore Solutions Inc
79.36M

Whales Holding TVGN

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Tevogen Bio Holdings Inc (TVGN) stock price today?

The current price of TVGN is 4.29 USD — it has decreased -1.72

What is Tevogen Bio Holdings Inc (TVGN)'s business?

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

What is the price predicton of TVGN Stock?

Wall Street analysts forecast TVGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVGN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Tevogen Bio Holdings Inc (TVGN)'s revenue for the last quarter?

Tevogen Bio Holdings Inc revenue for the last quarter amounts to -5.73M USD, decreased -5.85

What is Tevogen Bio Holdings Inc (TVGN)'s earnings per share (EPS) for the last quarter?

Tevogen Bio Holdings Inc. EPS for the last quarter amounts to USD, decreased

How many employees does Tevogen Bio Holdings Inc (TVGN). have?

Tevogen Bio Holdings Inc (TVGN) has 18 emplpoyees as of March 31 2026.

What is Tevogen Bio Holdings Inc (TVGN) market cap?

Today TVGN has the market capitalization of 17.29M USD.